This trial will study the effects of two drugs, Cyclophosphamide and Sirolimus, on thyroid cancer that has spread.
- Metastatic Medullary Thyroid Cancer
1 Primary · 3 Secondary · Reporting Duration: Patients will be followed until death or up to 2 years
1 Treatment Group
Cyclophosphamide and Sirolimus
1 of 1
19 Total Participants · 1 Treatment Group
Primary Treatment: Sirolimus · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What studies have been done on the long-term effects of Sirolimus?
"Sirolimus has received a score of 2 from our team at Power. This is because, although there is data supporting its safety, this medication has not yet been proven effective in clinical trials." - Anonymous Online Contributor
What is the total subject pool for this experiment?
"According to the clinicaltrials.gov website, this clinical trial is still looking for patients. This particular study was first posted on April 27th, 2017 and received its most recent update on August 15th, 2022. So far, 19 patients have been enrolled at 1 site." - Anonymous Online Contributor
For what purpose is Sirolimus most often prescribed?
"Sirolimus is a medication that's frequently used in organ transplantation procedures. Additionally, it has shown to be helpful for patients with multiple sclerosis, leukemia, myelocytic, acute conditions, and retinoblastoma." - Anonymous Online Contributor
Are new participants being accepted for this experiment?
"The online registry, clinicaltrials.gov, shows that this trial is open and looking for patients. This particular study was first advertised on April 27th, 2017 with the most recent update being from August 15th, 2022." - Anonymous Online Contributor